Author Archives: Joana Carvalho, PhD

Anifrolumab Reduces Disease Activity, Skin Lesion Severity, and Corticosteroid Use in SLE Patients, Phase 3 Trial Shows

Adding anifrolumab to standard-of-care treatment significantly reduced disease activity, corticosteroid use, and severity of skin lesions in people with moderate-to-severe systemic lupus erythematosus (SLE), according to data from a Phase 3 trial. The research, “Efficacy and Safety of Anifrolumab in Patients with Moderate to Severe Systemic Lupus…

Cognitive and Psychiatric Issues Linked to Autoantibodies in Brain Unique to Lupus Patients, Study Finds

Autoantibodies targeting certain regulatory RNAs — molecules that serve as the template for protein production — in the brains of lupus patients are unique to these people and involved in neuropsychiatric symptoms of the disease, a study reports. The study, “Neuronal BC RNA transport impairments caused by systemic lupus erythematosus autoantibodies,”…

New Biomarkers Predict Risk of Heart Disease in Juvenile-onset SLE

Scientists have found a new set of biomarkers that may be used to predict the risk of heart disease in patients with juvenile-onset systemic lupus erythematosus (JSLE). The findings were discussed in an oral presentation titled, “Metabolomics in juvenile-onset SLE: identifying new biomarkers to predict cardiovascular risk,”…